Browse our 650+ Publications​

Latest Publications

TET2 guards against unchecked BATF3-induced CAR T cell expansion

Jain N, et al.
Nature
August 2023
Authors and Affiliates
Nayan Jain 1,2, Zeguo Zhao 2, Judith Feucht 2,3, Richard Koche 4, Archana Iyer 2, Anton Dobrin 1,2, Jorge Mansilla-Soto 2, Julie Yang 4, Yingqian Zhan 4, Michael Lopez 2, Gertrude Gunset 2, Michel Sadelain 5; 1 Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. 2 Centre for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. 3 University Children's Hospital, Tübingen, Germany. 4 Centre for Epigenetics Research, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. 5 Centre for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Centre, New York, NY, USA. m-sadelain@ski.mskcc.org.

The overlap of skin and blood T-cell clones in early-stage mycosis fungoides.

Joffe D, et al.
Blood Advances
August 2023
Authors and Affiliates
Daniel Joffe BS1, Safiyyah Bhatti MD1,2, Lauren Banner BS1, Romsin Zaya BS1, Laura Gleason BS1, Anjali Mishra PhD2, Ilan Kirsch MD3, Pierluigi Porcu MD2, Neda Nikbakht MD, PhD1 1 - Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 2 - Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 3 - Adaptive Biotechnologies, Seattle, WA

A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia

Goral A, et al.
Frontiers in Immunology
August 2023
Authors and Affiliates
Agnieszka Goral 1, Malgorzata Firczuk 1, Klaudyna Fidyt 1, Marta Sledz 1, Francesca Simoncello 2, Karolina Siudakowska 1, Giulia Pagano 3, Etienne Moussay 3, Jérôme Paggetti 3, Patrycja Nowakowska 1, Stefania Gobessi 4, Joanna Barankiewicz 5, Aleksander Salomon-Perzynski 5, Federica Benvenuti 2, Dimitar G Efremov 4, Przemyslaw Juszczynski 5, Ewa Lech-Maranda 5, Angelika Muchowicz 1; 1 Department of Immunology, Medical University of Warsaw, Warsaw, Poland. 2 Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy. 3 Tumor-Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg. 4 Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy. 5 Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Analysis of thymic generation of shared T-cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild-type antigens

Mattila J, et al.
cancer medicine
August 2023
Authors and Affiliates
Joonatan Mattila 1, Silja Sormunen 2, Nelli Heikkilä 1 3, Ilkka P Mattila 4, Jari Saramäki 2, T Petteri Arstila 1; 1 Research Programs Unit, Translational Immunology, Haartmaninkatu 3 (PL 21) 00014, and Medicum, University of Helsinki, Helsinki, Finland. 2 Department of Computer Science, Aalto University, Espoo, Finland. 3 Faculty of Medicine, Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. 4 Department of Pediatric Cardiac and Transplantation Surgery, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy

Sharma S, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Sandhya Sharma 1,2, Mae Woods 2, Naren U Mehta 2, Tim Sauer 2, Kathan S Parikh 2, Michael Schmuck-Henneresse 2,3, Huimin Zhang 2, Birju Mehta 2, Malcolm K Brenner 2,4,5,6, Helen E Heslop 1,2,4,5,6, Cliona M Rooney 7,2,4,6,8,9; 1 Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital, Houston, Texas, USA. 3 Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Charitéplatz 1, Berlin, Germany. 4 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA. 5 Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. 6 Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA. 7 Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA crooney@bcm.edu. 8 Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. 9 Department of Pathology-Immunology, Baylor College of Medicine, Houston, Texas, USA.

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Bhatia V, et al.
Nature Communications
August 2023
Authors and Affiliates
Vipul Bhatia 1, Nikhil V Kamat 2, Tiffany E Pariva 1, Li-Ting Wu 1, Annabelle Tsao 1, Koichi Sasaki 3, Huiyun Sun 1, Gerardo Javier 1, Sam Nutt 1, Ilsa Coleman 1, Lauren Hitchcock 1, Ailin Zhang 1, Dmytro Rudoy 1, Roman Gulati 4, Radhika A Patel 1, Martine P Roudier 5, Lawrence D True 6, Shivani Srivastava 1, Colm M Morrissey 5, Michael C Haffner 1,6,7, Peter S Nelson 1,2,4,5,6,7, Saul J Priceman 8,9, Jun Ishihara 10, John K Lee 11,12,13,14; 1 Human Biology Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. 2 Division of Medical Oncology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. 3 Department of Bioengineering, Imperial College London, 86 Wood Lane, London, W12 0BZ, UK. 4 Public Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. 5 Department of Urology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. 6 Department of Pathology and Laboratory Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. 7 Clinical Research Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. 8 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. 9 Department of Immuno-Oncology, Beckman Research Institute of City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA. 10 Department of Bioengineering, Imperial College London, 86 Wood Lane, London, W12 0BZ, UK. j.ishihara@imperial.ac.uk. 11 Human Biology Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. jklee5@fredhutch.org. 12 Division of Medical Oncology, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. jklee5@fredhutch.org. 13 Department of Pathology and Laboratory Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA. jklee5@fredhutch.org. 14 Clinical Research Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. jklee5@fredhutch.org.

Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose

Werbel WA, et al.
American Journal of Transplantation
August 2023
Authors and Affiliates
William A Werbel 1, Andrew H Karaba 2, Teresa Po-Yu Chiang 3, Allan B Massie 4, Diane M Brown 2, Natasha Watson 5, Maggie Chahoud 2, Elizabeth A Thompson 2, Aileen C Johnson 6, Robin K Avery 2, Willa V Cochran 2, Daniel Warren 3, Tao Liang 2, Miguel Fribourg 7, Christopher Huerta 8, Hady Samaha 8, Sabra L Klein 8, Maria P Bettinotti 9, William A Clarke 9, Ioannis Sitaras 10, Nadine Rouphael 8, Andrea L Cox 11, Justin R Bailey 2, Andrew Pekosz 10, Aaron A R Tobian 9, Christine M Durand 2, Nancy D Bridges 5, Christian P Larsen 6, Peter S Heeger 12, Dorry L Segev 4; CPAT investigators; 1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: wwerbel1@jhmi.edu. 2 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3 Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4 Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA; Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA. 5 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 6 Department of Surgery, Emory University, Atlanta, Georgia, USA. 7 Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 8 Department of Medicine, Emory University, Atlanta, Georgia, USA. 9 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 10 W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 11 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Medicine, Emory University, Atlanta, Georgia, USA; Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 12 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

Pagliuca S, et al.
Nature Communications
August 2023
Authors and Affiliates
Simona Pagliuca 1,2,3, Carmelo Gurnari 1,4, Colin Hercus 5, Sébastien Hergalant 6, Sanghee Hong 7, Adele Dhuyser 3,8, Maud D'Aveni 2,3, Alice Aarnink 3,8, Marie Thérèse Rubio 2,3, Pierre Feugier 2, Francesca Ferraro 9, Hetty E Carraway 10, Ronald Sobecks 11, Betty K Hamilton 11, Navneet S Majhail 12, Valeria Visconte 1, Jaroslaw P Maciejewski 13; 1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 2 Department of Hematology, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 3 CNRS UMR 7365, IMoPA, Biopole of University of Lorraine, Vandœuvre-lès-Nancy, France. 4 Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. 5 Novocraft Technologies Sdn Bhd, Kuala Lumpur, Malaysia. 6 Inserm UMR-S 1256 Nutrition-Genetics-Environmental Risk Exposure, University of Lorraine, 54500, Vandœuvre-lès-Nancy, France. 7 Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 8 Histocompatibility Department, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 9 Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. 10 Leukemia Program, Hematology Department, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 11 Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 12 Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA. 13 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Lin Yi, et al.
Nature Medicine
August 2023
Authors and Affiliates
Yi Lin  1 , Noopur S. Raje2, Jesús G. Berdeja  3, David S. Siegel  4, Sundar Jagannath  5, Deepu Madduri5, Michaela Liedtke6, Jacalyn Rosenblatt7, Marcela V. Maus  2, Monica Massaro8, Fabio Petrocca8, Ashish Yeri8, Olivia Finney8, Andrea Caia9, Zhihong Yang9, Nathan Martin9, Timothy B. Campbell9, Julie Rytlewski9, Jaymes Fuller9, Kristen Hege9, Nikhil C. Munshi  10 & James N. Kochenderfer  11 1Mayo Clinic, Rochester, MN, USA. 2Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. 3Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA. 4Hackensack University Medical Center, Hackensack, NJ, USA. 5Mount Sinai Medical Center, New York City, NY, USA. 6Stanford University Medical Center, Palo Alto, CA, USA. 7Beth Israel Deaconess Medical Center, Boston, MA, USA. 8 2SeventyBio, Inc, Cambridge, MA, USA. 9Bristol Myers Squibb, Princeton, NJ, USA. 10Dana-Farber Cancer Institute, Boston, MA, USA. 11Surgery Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA."

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

Izutsu K, et al.
International Journal of Hematology
August 2023
Authors and Affiliates
Koji Izutsu1  Kazuhito Yamamoto2 Koji Kato3 Takayuki Ishikawa4 Noriko Fukuhara5 Yasuhito Terui6,7 Ilseung Choi8· Sumiko Okubo9 Natsumi Ogawa10 Mizu Sakai10 Yasuko Nishimura10 Brenda Chyla11 Yan Sun11 Dai Maruyama1,6 1 Department of Hematology, National Cancer Center Hospital, Tokyo, Japan2 Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan3 Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan4 Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan5 Department of Hematology, Tohoku University Hospital, Miyagi, Japan6 Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan7 Department of Hematology, Saitama Medical University Hospital, Saitama, Japan8 Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan9 AbbVie GK, Osaka, Japan10 AbbVie GK, Tokyo, Japan11 AbbVie, Inc, North Chicago, IL, USA
Previous Next